Scarica l'app Stockscreener
10.95
4.29%
0.45
Dopo l'orario di chiusura:
10.60
-0.35
-3.20%
Precedente Chiudi:
$10.50
Aprire:
$10.515
Volume 24 ore:
1.05M
Relative Volume:
2.10
Capitalizzazione di mercato:
$862.53M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+22.35%
1M Prestazione:
+67.43%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$10.38
$10.98
Intervallo di 1 settimana:
$9.06
$10.98
Portata 52W:
$5.33
$10.98
Niagen Bioscience Inc Stock (NAGE) Company Profile
Nome
Niagen Bioscience Inc
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Confronta NAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
10.95 | 704.99M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Niagen Bioscience (NASDAQ:NAGE) Sets New 12-Month HighWhat's Next? - MarketBeat
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript - MSN
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Niagen Bioscience Reaches Analyst Target Price - Nasdaq
Ratios Uncovered: Breaking Down Niagen Bioscience Inc (NAGE)’s Trailing Twelve Months Metrics - DWinneX
Niagen Bioscience: Q1 Earnings Snapshot - New Haven Register
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook - BioSpace
Niagen Bioscience Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Niagen Bioscience Q1 2025 sales surge, stock rises - Investing.com Nigeria
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings: EPS of $0.07 Beats Estimate, Revenue Surges to $30.5 Million - GuruFocus
Niagen Bioscience (NAGE) Reports Record Q1 Revenue with Strong G - GuruFocus
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Niagen Bioscience Q1 2025 slides: revenue jumps 38%, raises full-year outlook - Investing.com
Niagen Bioscience, Inc. SEC 10-Q Report - TradingView
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 | NAGE Stock News - GuruFocus
What's Next: Niagen Bioscience's Earnings Preview - Nasdaq
Niagen Bioscience Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Niagen Bioscience (NAGE) Expands Clinical Network with New Clinics - GuruFocus
Niagen IV therapy expands to nearly 600 clinics nationwide By Investing.com - Investing.com India
Niagen IV therapy expands to nearly 600 clinics nationwide - Investing.com
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide | NAGE Stock News - GuruFocus
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide - Nasdaq
Niagen Bioscience (NAGE) Expands Clinical Network with New Clini - GuruFocus
Niagen Bioscience adds aging expert to advisory board By Investing.com - Investing.com India
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board | NAGE Stock News - GuruFocus
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advis - GuruFocus
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board - The Joplin Globe
Niagen Bioscience adds aging expert to advisory board - Investing.com
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - Bluefield Daily Telegraph
Is Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Niagen Bioscience Inc [NAGE] stock for 2,146 USD was acquired by Lopez Carlos Luis - knoxdaily.com
Is it possible to buy Niagen Bioscience Inc(NAGE) shares at a good price now? - uspostnews.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap up US$51m last week, benefiting both individual investors who own 36% as well as insiders - Yahoo Finance
Supplement Maker Rebrands - Los Angeles Business Journal
Robert Fried Exercises Options, Realizes $173KNiagen Bioscience (NASDAQ:NAGE) - Benzinga
Market Resilience: Niagen Bioscience Inc (NAGE) Finishes Weak at 5.42, Down -3.56 - DWinneX
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - marketscreener.com
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire
Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com South Africa
Niagen Bioscience Stands Firm Despite Global Tariff Concerns - Finimize
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - MarketScreener
Niagen Bioscience maintains stability amid tariffs - Investing.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues - simplywall.st
Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari
Non sono disponibili dati finanziari per Niagen Bioscience Inc (NAGE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Niagen Bioscience Inc Azioni (NAGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):